KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Non-Current Assets (2018 - 2025)

Castle Biosciences' Other Non-Current Assets history spans 7 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 206.92% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, up 206.92%, while the annual FY2025 figure was $3.8 million, 206.92% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $3.8 million at Castle Biosciences, up from $1.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.8 million in Q4 2025 and bottomed at $792000.0 in Q1 2023.
  • The 5-year median for Other Non-Current Assets is $1.5 million (2023), against an average of $1.7 million.
  • The largest annual shift saw Other Non-Current Assets soared 719.6% in 2021 before it tumbled 70.66% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.7 million in 2021, then crashed by 35.28% to $1.1 million in 2022, then grew by 29.73% to $1.4 million in 2023, then fell by 14.72% to $1.2 million in 2024, then soared by 206.92% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Other Non-Current Assets are $3.8 million (Q4 2025), $1.3 million (Q3 2025), and $1.2 million (Q2 2025).